These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22047646)

  • 1. The presence and location of epithelial implants and implants with epithelial proliferation may predict a higher risk of recurrence in serous borderline ovarian tumors: a clinicopathologic study of 188 cases.
    Quddus MR; Sung CJ; Zhang C; Moore RG; Ou JJ; Steinhoff MM; Lawrence WD
    Hum Pathol; 2012 May; 43(5):747-52. PubMed ID: 22047646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymph node involvement in ovarian serous tumors of low malignant potential: a clinicopathologic study of thirty-six cases.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2010 Jan; 34(1):1-9. PubMed ID: 19898226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
    Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
    Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micropapillary pattern in serous borderline ovarian tumors: does it matter?
    Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
    Gynecol Oncol; 2011 Dec; 123(3):511-6. PubMed ID: 21917305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
    Kennedy AW; Hart WR
    Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Borderline epithelial tumours of the ovary--a retrospective analysis of 31 cases.
    Kane SV; Bharadwaj R; Tongaonkar HB
    Indian J Cancer; 1999 Mar; 36(1):18-31. PubMed ID: 10810551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian serous borderline tumors with invasive peritoneal implants.
    Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
    Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
    Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
    Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors.
    Ren J; Peng Z; Yang K
    Gynecol Oncol; 2008 Aug; 110(2):162-7. PubMed ID: 18495223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD; Petrescu A; Waller M; Dina I
    Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial ovarian tumors of borderline malignancy: long-term follow-up.
    Casey AC; Bell DA; Lage JM; Fuller AF; Nikrui N; Rice LW
    Gynecol Oncol; 1993 Sep; 50(3):316-22. PubMed ID: 8406194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benign ovarian serous tumors: a re-evaluation and proposed reclassification of serous "cystadenomas" and "cystadenofibromas".
    Seidman JD; Mehrotra A
    Gynecol Oncol; 2005 Feb; 96(2):395-401. PubMed ID: 15661227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study.
    Fauvet R; Boccara J; Dufournet C; David-Montefiore E; Poncelet C; Daraï E
    Cancer; 2004 Mar; 100(6):1145-51. PubMed ID: 15022280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavior of serous borderline ovarian tumors with and without micropapillary patterns: results of a French multicenter study.
    Fauvet R; Demblocque E; Morice P; Querleu D; Daraï E
    Ann Surg Oncol; 2012 Mar; 19(3):941-7. PubMed ID: 21879267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.
    Seidman JD; Kurman RJ
    Hum Pathol; 2000 May; 31(5):539-57. PubMed ID: 10836293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathologic analysis of 130 cases of mucinous borderline ovarian tumors].
    Cao DY; Shen K; Tao T; Yang JX; Xiang Y; Huang HF; Wu M; Pan LY; Lang JH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):15-8. PubMed ID: 21429428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of peritoneal extensions for the diagnosis and management of serous ovarian borderline tumors].
    Andrei S; Stolnicu S; Rădulescu D; Mocan S; Puşcaşu L
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):679-86. PubMed ID: 17571566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.